Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.56 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.56 |
| ▸ | WNT3A | P56704 | 2/20 | 0.56 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14922413 | 0.90 | CYP19A1 (0.51) | ACHECTNNB1WNT3ACALM1CYP19A1 | |
| SCHEMBL25246209 | 0.87 | CYP19A1 (0.60) | ACHECYP19A1KMT2AMEN1NPC1 | |
| SCHEMBL499794 | 0.86 | LMNA (0.55) | KMT2AMEN1LMNAMAPT | |
| SCHEMBL6202582 | 0.86 | ACHE (0.59) | ACHECTNNB1WNT3AKMT2AMEN1 | |
| SCHEMBL19230479 | 0.85 | ACHE (0.55) | ACHECTNNB1WNT3ACYP19A1KMT2A | |
| SCHEMBL29803233 | 0.85 | ACHE (0.55) | ACHECTNNB1WNT3ACYP19A1KMT2A | |
| SCHEMBL14814530 | 0.85 | MAPT (0.60) | ACHECTNNB1WNT3AKMT2AMEN1 | |
| SCHEMBL14922414 | 0.82 | LMNA (0.48) | CTNNB1WNT3AKMT2AMEN1LMNA | |
| SCHEMBL8403835 | 0.80 | ALDH1A1 (0.50) | ACHECTNNB1WNT3AKMT2AMEN1 | |
| SCHEMBL22463054 | 0.80 | ALDH1A1 (0.50) | ACHECTNNB1WNT3AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| EP-3875456-A1 | HETERO-BIFUNCTIONAL PROTEOLYSIS-TARGETING CHIMERAS (PROTACS) FOR THE SELECTIVE DEGRADATION OF FK506-BINDING PROTEINS (FKBPS) | Technische Universität Darmstadt (DE) | 2021-09-08 | — | — | EP | disclosed |
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-20 | — | — | US | disclosed |
| WO-2021067405-A1 | NEUROPROTECTIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| WO-2021067439-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2021-04-01 | — | — | US | disclosed |
| US-20200308144-A1 | Multimeric piperidine derivatives | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2020-10-01 | — | — | US | disclosed |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAPAFUSYN PHARMACEUTICALS, INC. | 2020-02-06 | — | — | US | disclosed |
| EP-3030556-B1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | UNIV DARMSTADT TECH (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3030556-B1 | SELECTIVE FKBP51 LIGANDS FOR TREATMENT OF PSYCHIATRIC DISORDERS | UNIV DARMSTADT TECH (DE) | 2019-10-30 | — | — | EP | disclosed |
| US-20090162858-A1 | Orthogonal chemical inducer of dimerization | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2009-06-25 | — | — | US | disclosed |
| EP-0776327-B1 | NEW MULTIMERIZING AGENTS | ARIAD GENE THERAPEUTICS INC (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040006233-A1 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | disclosed |
| US-20030036654-A1 | Synthetic multimerizing agents | HOLT DENNIS A (US) | 2003-02-20 | — | — | US | disclosed |
| US-20020161240-A1 | Synthetic multimerizing agents | ARIAD GENE THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-6150527-A | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6133456-A | DIMERS OF THE MACROCYCLIC NATURAL PRODUCT, FK506, COVALENTLY ATTACHED TO EACH OTHER VIA A SYNTHETIC LINKER MOIETY | ARIAD GENE THERAPEUTICS, INC. (US) | 2000-10-17 | — | — | US | disclosed |
| EP-0888303-A1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS | ARIAD GENE THERAPEUTICS, INC. (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997031899-A1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERISING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN DERIVED DOMAINS | ARIAD GENE THERAPEUTICS, INC. (US) | 1997-09-04 | — | — | WO | disclosed |
| WO-1997031898-A1 | SYNTHETIC DERIVATIVES OF RAPAMYCIN AS MULTIMERIZING AGENTS FOR CHIMERIC PROTEINS WITH IMMUNOPHILIN-DERIVED DOMAINS | ARIAD GENE THERAPEUTICS, INC. (US) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066416-B2 | Rapafucin derivative compounds and methods of use thereof | RICTOR, FKBP14, MTOR | ACHE 4884/4885CTNNB1 4844/4885WNT3A 4143/4885 |
| US-20020161240-A1 | Synthetic multimerizing agents | SSB, F13B, LCP2 | ACHE 4848/4885CTNNB1 2896/4885WNT3A 4198/4885 |
| US-20200308144-A1 | Multimeric piperidine derivatives | FKBP14, FKBP5, FKBP3 | ACHE 4827/4885CTNNB1 1376/4885WNT3A 2081/4885 |
| US-20200040004-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | ACHE 4884/4885CTNNB1 4844/4885WNT3A 4143/4885 |
| US-20040006233-A1 | Synthetic multimerizing agents | FKBP1B, FKBP2, FKBP14 | ACHE 4880/4885CTNNB1 4433/4885WNT3A 4781/4885 |
| US-20230000996-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | ACHE 4884/4885CTNNB1 4844/4885WNT3A 4143/4885 |
| US-20210094933-A1 | RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF | RICTOR, FKBP14, MTOR | ACHE 4884/4885CTNNB1 4844/4885WNT3A 4143/4885 |
| US-20030036654-A1 | Synthetic multimerizing agents | FKBP1B, FKBP2, FKBP14 | ACHE 4878/4885CTNNB1 4323/4885WNT3A 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.